eSolutions, mHealth & HealthIT

Abstract

Hun og en håndfuld andre lokale er blevet en form for spydspidser for modstanden i en dialoggruppe foranlediget af Varde Kommune, og hun fortæller, hvordan folk i den lille by er vrede, ulykkelige og yderst utrygge ved planerne, der dog endnu kun er på tegnebrættet. Men i løbet af de seneste par måneder er dét, der for foreningens talsperson Søren Bak Sommer startede som en lokal sag, vokset og har både påkaldt sig opmærksomhed fra folketingsmedlemmer og fra borgere i andre dele af landet, hvor der også er planer om datacentre. Og selvom regeringen med en akutplan for elnettet i foråret satte datacentre bagest i køen, og erhvervsminister Martin Lidegaard har bebudet en national datacenter-strategi, bliver det lokale demokrati sat under pres i kommunerne, hvor det vælter ind med ansøgninger om at bygge datacentre, mener Søren Bak Sommer. - Vi står i en situation, hvor vi hver eneste uge ser nye overskrifter omkring, hvordan verdens tilstand er på klimafronten, og så nytter det jo ikke noget, at vi kaster hyperskala-datacentre ind - den mest energitunge ting, menneskeheden nogensinde har frembragt - i en tid, hvor vi er nødt til at nedsætte vores energiforbrug.

Abstract

AI-bolaget Anthropic rapporterar tidiga framsteg i arbetet med att påskynda läkemedelsutveckling med AI-modellen Claude. Bolaget samarbetar med sex aktörer, däribland Bristol Myers Squibb, Generate Biomedicines och Enveda, och driver även egna forskningsprojekt. I ett projekt med Generate Biomedicines tog Claude fram en design för CAR-T-behandling där den genetiska instruktionen var omkring 70 procent kortare än standardversionen och i laboratoriet gav cirka tio gånger fler receptorer på immuncellerna. Divergence Labs använde samtidigt Claude för att generera omkring 35 000 antikroppsdesigner på en månad och Enveda har minskat tiden för mänsklig dokumentgranskning med 89 procent.

Abstract

A 2025 graduate of Harvard's joint MS/MBA biotechnology program, he previously worked at Prime Medicine, a Cambridge-based gene-editing company developing therapies based on prime editing, and at Casdin Capital, a New York life-sciences investment firm focused on biotech and genomics. Mithril's team designed and oversaw the experiments, contract laboratories produced the antibodies, measured their binding, ran cell-based assays and conducted the mouse studies. Researchers assigned treatment by litter without randomization and tested the antibody group 126 to 161 days after the control group, with a colony relocation in between. When a team member overruled its recommendation to measure how quickly all 113 bound to and detached from their targets, Claude revised the plan and related drafts to cover 89 within four minutes.

Abstract

Developing a drug involves many varied tasks: doing early research to identify a target for a drug and the right type of drug to engage it, designing a molecule with the right properties, optimizing it to be manufactured reliably at scale, drafting the regulatory filings needed to run clinical trials, designing and administering those trials, and much more. First, it lets us better understand the strengths and limitations of our models in relation to a much wider range of drug development tasks (we've already prioritized specific improvements to our models based on what we've learned so far). One design was about 70% shorter than the standard version, and in lab tests it was more effective: it allowed immune cells to make roughly 10 times as many receptors (the proteins they use to spot cancer cells), it killed tumor cells more efficiently, and the immune cells remained active for longer. BigHat's scientists and an Anthropic researcher worked with Claude to improve these three properties in two leads, both antibody fragments that could become parts of future drugs: one designed to target cancer cells, and one designed to keep a drug in the body longer.

Abstract

Simply mentioning the letters A" and "I" close together in a sentence can provoke emotional pro/con reactions: Working with the tech can make you a forward-looking pragmatist or an (expletive) traitor depending on the person in the room. "It has become something that feels more like a responsibility, given that AI is probably going to have an outsized influence on the shape of humanity's future." Finding the Blind Spots These physicians see AI training as a significant personal responsibility, but they're quick to point out it's not for everyone. If you are someone who is tech-savvy, who is not afraid of picking up new things and making mistakes along the way, then I think it would be a good fit." Lin knows several physicians who've joined these projects and quickly realized that the reasoning required is nothing like clinical reasoning. "There is the less fun aspect of AI training that crosses over into all types of medicine: the ability to repeat a process precisely countless times without losing the focus required to find errors and anomalies." Then there's the uncertainty."